Table 3.

Pharmacokinetic (PK) data for rucaparib with and without bevacizumab co-administration

PK parameter, mean (±SD)	Rucaparib first administration			Rucaparib at steady state
	Day −7			Day 1			Day 21
	Rucaparib 400 mg BID	Rucaparib 500 mg BID	Rucaparib 600 mg BID	Rucaparib 400 mg BID	Rucaparib 500 mg BID	Rucaparib 600 mg BID	Rucaparib 400 mg BID	Rucaparib 500 mg BID	Rucaparib 600 mg BID
n	3	3	3	3	3	3	2a	3	2b
Cmax (µg/mL)	0.7 ± 0.1	0.9 ± 0.6	1.0 ± 0.2
CmaxSS (µg/mL)				2.4 ± 0.2	2.6 ± 0.5	2.6 ± 0.5	2.6 ± 0.9	2.3 ± 0.4	2.5 ± 1.3
Cmin (µg/mL)	0.2 ± 0.1	0.4 ± 0.1	0.3 ± 0.2
CminSS (µg/mL)				1.4 ± 0.3	1.6 ± 0.7	1.4 ± 0.3	1.3 ± 0.4	1.5 ± 0.5	1.6 ± 1.2
Tmax (h)	3.4 ± 0.7	1.9 ± 0.1	3.4 ± 1.2	4.6 ± 2.9	1.7 ± 1.2	3.0 ± 1.0	3.0 ± 1.3	2.0 ± 1.0	5.0 ± 1.4
AUC0–8h (µg/mL*h)	3.4 ± 0.8	4.7 ± 1.9	4.9 ± 1.6
AUCSS (µg/mL*h)				15.5 ± 0.8	16.7 ± 4.6	14.9 ± 2.6	14.8 ± 3.1	14.2 ± 3.2	15.8 ± 9.6
Ctrough (µg/mL)c				1.6 ± 0.1	1.8 ± 0.7	1.6 ± 0.1	1.5 ± 0.3	2.0 ± 0.6	2.1 ± 0.3

AUC_0–8h area under the concentration–time curve from zero to 8 hours, BID twice daily, C_min minimum plasma concentration, C_max maximum plasma concentration, C_trough trough concentration, SD standard deviation, SS steady state, T_max time to C_max

^aPatient 0001-002 was not included in the calculation of the mean of the PK parameters because rucaparib administration was suspended for the whole week before day 21

^bPatient 0001-008 was not included in the calculation of the mean of the PK parameters because rucaparib was suspended on day 21 for dose-limiting toxicity

^cMean C_trough is calculated by mediating the rucaparib concentration values on day 1 and 21 of the cycle